Partners

http://www.ema.europa.eu/ema/

https://www.abbvie.com/

http://www.aifa.gov.it/en

http://www.amgen.com/

http://pharma.bayer.com/

http://casmi.org.uk/

http://www.lygature.org

https://www.boehringer-ingelheim.com/

https://www.efpia.eu/

http://servier.com/en/

https://www.astellas.eu/

https://www.has-sante.fr//portail/

https://www.eurordis.org/

https://www.astrazeneca.com/

http://www.ipsen.com/

http://www.eu-patient.eu/

http://www.janssen.com/

https://lillypad.eu/our-work/

https://www.pfizer.com/

http://newdigs.mit.edu/

https://www.gsk.com/

http://www.lysogene.com/

http://www.merck.com/index.html

https://www.merckgroup.com/en

https://www.roche.com/index.htm

https://www.nice.org.uk/

https://www.novartis.com/

https://www.zorginstituutnederland.nl/

http://www.lundbeck.com/global

https://www.novonordisk.com/

http://www.ucbpharma.com/

https://www.sanofi.com/en/

https://www.shire.com/

Welcome

About this infographic

This infographic reflects the key lessons and primary outcomes from the ADAPT SMART consortium, e.g. reports, discussion papers, workshop summaries etc. The views expressed here are the result from collective input from the ADAPT SMART consortium and do not necessary reflect the views of individual partner organizations.

About ADAPT SMART

Accelerated Development of Appropriate Patient Therapies a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes

The ADAPT SMART project launched in September 2015. It is an enabling platform that supports activities related to Medicines Adaptive Pathways to Patients (MAPPs) within the Innovative Medicines Initiative (IMI). MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life span in a sustainable fashion.

The 30-month project funded through IMI aims to facilitate and accelerate the availability of MAPPs to all healthcare stakeholders. ADAPT SMART supported projects under the second Innovative Medicines Initiative (IMI2) investigating MAPPs tools and methodologies. ADAPT-SMART aligned a number of major stakeholders eager to progress towards MAPPs implementation. The ADAPT-SMART Coordination and Support Action (CSA), will act as a neutral collaborative framework to establish the platform that will engage with all relevant stakeholders, including patients, industry, regulators, Health Technology Assessment bodies (HTAs), payers (national and European Networks), clinicians, governments/policy makers.

In addition to engaging in a dialogue with relevant stakeholders, the ADAPT-SMART consortium contributed to align understanding of the impact of MAPPs, to share learnings between all stakeholders, and to allow the field to actively work towards MAPPs implementation.

Additional information

Review of IMI projects

Within ADAPT SMART, outputs from other IMI projects were analysed to perform a gap analysis of tools and methods that could benefit MAPPs. Several IMI outputs have been identified that could contribute the MAPPs agenda.

You can find the review of IMI projects here

ADAPT SMART glossary

The ADAPT SMART glossary was created with working definitions for common terms relevant for the consortium to facilitate the discussion and further communications on MAPPs. The glossary was developed with agreed operational definitions of the terms used in international literature and based on the input from members of the ADAPT SMART consortium representing different stakeholder groups. Some definitions have been created without any direct reference source (shown as ‘ADAPT SMART’) and where applicable, an EU perspective was chosen..

You can find the glossary here

Funding

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.